What is Axsome Therapeutics Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Axsome Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.07.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Axsome Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Axsome Therapeutics's Cash-to-Debt or its related term are showing as below:
AXSM'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.58 Med: 2.77 Max: No Debt
Current: 2.07
During the past 11 years, Axsome Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.58. And the median was 2.77.
Axsome Therapeutics Cash-to-Debt Historical Data
The historical data trend for Axsome Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Axsome Therapeutics Cash-to-Debt Chart
|
Axsome Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
11.03 |
3.67 |
1.74 |
2.12 |
2.07 |
|
Axsome Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
2.12 |
1.67 |
2.37 |
2.25 |
2.07 |
Competitive Comparison of Axsome Therapeutics's Cash-to-Debt
For the Biotechnology subindustry, Axsome Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Cash-to-Debt falls into.
Axsome Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Axsome Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Axsome Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (Axsome Therapeutics) Business Description
Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
| Susan Mahony |
director |
LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
| Mark Coleman |
director |
25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
| Hunter R. Murdock |
officer: General Counsel |
22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007 |
| Roger Jeffs |
director |
|
| Nick Pizzie |
officer: Chief Financial Officer |
25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
| Mark E Saad |
director |
C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
| Herriot Tabuteau |
director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER |
|
| Mark L. Jacobson |
officer: Chief Operating Officer |
200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038 |
| David C Marek |
officer: Chief Commercial Officer |
C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
| John Golubieski |
officer: Chief Financial Officer |
C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
| Myrtle S Potter |
director |
10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
| Randall Kaye |
officer: Chief Medical Officer |
11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
| Ames Constance |
officer: Vice President, Finance |
25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
| Antecip Capital Llc |
10 percent owner |
630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111 |
Axsome Therapeutics (Axsome Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AXSM has been successfully added to your